Lexaria Bioscience Corp. has completed a registered direct offering with a single institutional investor, raising $2 million through the sale of 2 million shares of common stock at $1.00 per share. The funding comes at a critical time for the drug delivery technology company, which secured the investment without significant shareholder dilution.
CEO Richard Christopher highlighted the strategic nature of the transaction, emphasizing the company's ability to secure funding during a difficult market period. Notably, the offering minimized potential shareholder impact by avoiding the issuance of additional warrants beyond pre-funded options.
H.C. Wainwright & Co. served as the exclusive placement agent for the offering. The company intends to use the net proceeds for working capital and general corporate purposes, which could support ongoing research and development of its DehydraTECH drug delivery platform.
The offering was conducted under a previously filed SEC shelf registration statement, ensuring compliance with regulatory requirements. This funding represents a strategic move for Lexaria to maintain financial flexibility and continue advancing its innovative drug delivery technology.
The successful capital raise underscores the company's resilience and potential in the competitive biotechnology landscape, providing resources to potentially further develop its patented technology that aims to improve drug absorption and reduce side effects.
